Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors. In this study, we genotyped 51 patients from an observational trial on cisplatin/5-FU-based neoadjuvant radiochemotherapy of locally advanced esophageal cancer (cT2-4, Nx, M0) and genotyping was correlated with histomorphological tumor regression. The C-allele frequency in esophageal cancer patients was 0.49. Pearson's w 2 -test showed a significant (Po0.05) association between tumor regression grades and T393C genotypes. Overall, 63% of the patients in the T-allele group (TT þ CT) were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(À) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%. The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.
Introduction
Esophageal cancer is among the 10 most frequent malignancies worldwide and it is the seventh leading cancer-related death in males in the United States.
1,2 Over the last two decades, esophageal adenocarcinoma has been the most rapidly increasing cancer in incidence in North America and Western Europe. 3, 4 Once diagnosed, the 5-year survival rate for patients with esophageal cancer was about 10%. 1 Especially patients with locally advanced esophageal cancer have a poor prognosis when treated exclusively by surgical resection. Therefore, neoadjuvant treatment strategies using chemo-and/or radiotherapy were developed 5, 6 with the aim to downstage the primary tumor, increase the resectability rate, eliminate micrometastases and improve survival. 7, 8 Results from prospective trials are encouraging, as patients with a complete pathological response have been consistently found to have survival rates up to 60%. 9, 10 They also showed that a prognostic benefit for multimodal therapy can be expected only in patients who respond to preoperative therapy and have a subsequent complete tumor resection. [11] [12] [13] [14] In some studies even after complete tumor resection, the prognosis of non-responders to preoperative treatment appears to be inferior to that of patients who had a surgery alone. 11, 15 As these therapies are expensive and associated with increased therapy-associated complication rates, 16 pretherapeutic molecular markers indicating response or non-response to neoadjuvant treatment of esophageal cancer would be helpful in selecting patients for future treatment protocols. 17, 18 In recent studies, an association between single-nucleotide polymorphisms in radiation-and chemotherapy-dependent pathways and clinical outcomes of esophageal cancer patients have been shown. 19 It has also been reported that the cAMP signaling pathway participates in the regulation of apoptosis. The generation of cAMP is catalyzed by adenylate cyclases, which are activated by ubiquitously expressed stimulatory G proteins. cAMP activates cAMP-dependent protein kinases (PKA), which phosphorylate various targets that contribute to the regulation of different cellular responses, including radiationinduced apoptosis. 20 Increased G protein-induced cAMP levels were reported to exert protective effects against radiation-induced apoptosis. 21 The modulation of cAMP has also been reported to interfere with cisplatin cytotoxicity. 22, 23 As stimulatory G proteins play an important role in the production of cAMP, polymorphisms in the gene GNAS1, encoding the G-protein subunit Galphas (Gs), might be related to therapy outcome.
The T393C polymorphism of the gene GNAS1 has been intensively studied for different tumor types. These studies showed that the T393C polymorphism is an independent prognostic factor for clinical outcome for various solid tumors. [24] [25] [26] [27] [28] To analyze the value of the T393C polymorphism as a predictive molecular marker for cisplatin/5-FU-based treatment in esophageal cancer, the aim of this study was to investigate a potential association between genotypes of the T393C polymorphism with histopathological tumor response to cisplatin/5-FU-based chemoradiation in esophageal cancer.
Results
Genotype distribution and subject characteristics Genotype classification, tumor characteristics and regression grades are displayed in Table 1 . The frequency of the C allele (fC) in the whole patient group was 0.49, which is not significantly different from that of healthy blood donors. 26 The distribution was compatible with the Hardy-Weinberg equilibrium. The comparison of gender showed a significant correlation with T393C genotypes. The TT genotype was associated with a higher proportion of females compared with TC and CC genotypes. There was no female with CC genotype in the whole case group. Dichotomization between T þ (TT þ CT) and TÀ genotypes (CC) showed significant (Po0.05) lower response rates for T-allele carriers. Twenty-six (63.4%) of the 41 T þ patients had an MiHR, whereas for TÀ genotypes an MiHR was seen only in two (20%) cases.
In binary logistic regression analysis, which contained pretherapeutic parameters as covariates (histology, genotype, gender), the T393C genotype kept its independence (Po0.05) with a hazard ratio of 7.25 (95% CI (confidence interval) 1.30-40.62) for CC genotypes to have an MaHR versus 1 (reference) for CT/TT genotypes.
There was no significant correlation between T393C genotypes and lymph node status (ypN), histology and tumor invasion (ypT).
TT and CC genotypes showed a trend toward less lymph node metastasis, which was not statistically significant ( Figure 1 ). The median number of tumor positive lymph nodes for TT genotypes was 0 (min 0, max 9), for CC genotypes 0.5 (min 0, max 4) and for CT genotypes 2 (min 0, max 2.5). Dichotomization between T þ (TT þ CT) and TÀ genotypes (CC) showed a higher median number of metastatic lymph nodes for T-allele carriers with a median of 1 (min 0, max 25) compared with the CC genotype with a median of 0.5 (min 0, max 4).
Clinical outcome by T393C genotypes and histopathological regression
The 5-year survival rate for all patients was 26% (95% CI 12-45%). The 5-year survival rate for CC genotypes was 20 and 28% for CT/TT genotypes. Survival was not significantly associated with T393C genotypes.
Kaplan-Meier curves depending on histopathological regression are shown in Figure 2 . There were significant better survival rates for patients with MaHR (Po0.05). The 5-year survival rate was 18% (95% CI 5-35%) for patients with MiHR and 38% (95 CI 18-60%) for patients with MaHR.
Discussion
Neoadjuvant treatment strategies for esophageal cancer are a matter of ongoing debate with controversial results from phase II and III trials. However, there is consensus that patients with MaHR to neoadjuvant chemoradiation benefit from these treatment modalities with 5-year survival rates up to 60%. 9, 10, 29, 30 Therefore, current efforts are focused on the detection and validation of biomarkers to design individualized therapy strategies. 31 The common T393C polymorphism in the gene GNAS1 is a genetic host factor. The aim of this study was to investigate whether the T393C polymorphism is predictive for response to cisplatin/5-FUbased neoadjuvant chemoradiation in locally advanced esophageal cancer.
The gene GNAS1 is mapped to chromosome 20q13 and consists of 13 exons. Somatic activating mutations of GNAS1 have been implicated in the etiology of McCune Albright Syndrome 32 and sporadic isolated endocrine tumors, 33, 34 which supports a role of GNAS1 in tumor initiation and progression. GNAS1 T393C polymorphism and esophageal cancer
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Recent studies have shown that genotypes of the T393C polymorphism are significantly associated with survival of patients suffering from bladder cancer, clear cell renal carcinoma, colorectal cancer, intrahepatic cholangiocarcinoma or invasive breast carcinoma. In these studies, T allele carriers were associated with an unfavorable clinical course in invasive breast cancer 27 and intrahepatic cholangiocarcinoma, 28 whereas homozygous T-allele carriers were at lowest risk for death in the other tumors [24] [25] [26] -suggesting that the biological effect of the T393C polymorphism may act differently in different tumor types.
In vitro experiments suggest that expression of Gs is associated with apoptosis. 35, 36 The second messenger cAMP, which is generated by activated Gas, seems to play a major role in this proapoptic process. In several cell types, including leukemic cells, 37 ovarian cancer cells 38 and lymphoma cells, 32 an increased concentration of the second messenger cAMP promotes apoptosis.
In contrast to these findings, it is well known that cAMP protects against radiation-induced cell death. 21 The underlying mechanism was only recently elucidated, showing that Gs inhibits radiation-induced apoptosis by restraining downregulation of Bcl-xl. 39 The cAMP-dependent protein kinase signaling pathway also seems to be involved in the acquisition of cisplatin resistance after irradiation. 40 It has been recently shown that the CC genotype of T393C polymorphism shows the lowest GNAS1 expression. 24 This is likely to lead to a lower cAMP production in CC carriers, which implies a decreased protective effect against radiation-and cisplatin-induced cell death. This might be an explanation for the increased number of major responders carrying the CC genotype in the present study.
Despite a more than 90% reduction of vital tumor cells, objective downstaging of the T category-aside from pathological complete remission-is a rare exception for neoadjuvant radiochemotherapy, whereas elimination of metastases in lymph nodes is statistically associated significantly with histomorphological response to neoadjuvant radiochemotherapy. 9 CT genotypes had clearly more lymph nodes with metastases after radiochemotherapy than the other both genotypes. This observation was not statistically significant, but it is in accordance with the described significant correlation between genotypes and response to neoadjuvant radiochemotherapy with worst response to neoadjuvant radiochemotherapy for T þ genotypes.
In conclusion, our findings strongly support the concept of T393C polymorphism to be a genetic host factor, which is predictive for histopathological response to cisplatin/5-FUbased radiochemotherapy in esophageal cancer. Further studies will have to confirm this hypothesis.
Materials and methods

Patients
Fifty-one patients in good general health condition (ECOG) performance status (0-1) with locally advanced, resectable esophageal cancer (cT2-4, Nx, M0) were recruited from a prospective trial on neoadjuvant radiochemotherapy of esophageal cancer followed by surgery from 1996 to 2003. Clinical staging was based on barium swallow, endoscopic ultrasound and CT of the chest and abdomen. Diagnostic laparoscopy was performed in all patients with adenocarcinomas to exclude peritoneal carcinomatosis.
All patients (median age 59 years; range 38-73 years; gender 42 (82%) men and 9 (18%) women) received standardized neoadjuvant radiochemotherapy. Cisplatin (20 mg m À2 day
À1
) was administered as short-term infusion on days 1-5 and 5-FU (1000 mg m À2 day À1 ) as continuous infusion over 24 h on days 1-5. Radiation was administered by linear accelerators with 10-15 MV and delivered in daily fractions of 1.8 Gy (days 1-5, 8-12, 15-19 and 22-26) with a total dose of 36 Gy using multiple field technique. Standardized transthoracic en bloc esophagectomy with two-field lymphadenectomy and reconstruction by gastric tube interposition with either left cervical or high intrathoracic anastomosis was performed 4-5 weeks following completion of radiochemotherapy in all patients. Informed consent was obtained from each patient, and the scientific protocol was approved by the local ethic committee.
Histomorphological grading of tumor regression
Resected surgical specimens were fixed in neutral-buffered formaldehyde and embedded in paraffin. Sections (5 mm) of resected specimens were stained with hematoxylin and eosin. These sections were used for both histopathological staging according to the tumor-node-metastasis classification system (UICC, 5th edition, 1997) and histomorphological evaluation of the effect of radiochemotherapy.
As clinical response evaluation after neoadjuvant therapy for esophageal cancer is known to be highly inaccurate, [41] [42] [43] [44] objective histopathological response analysis was applied using morphological criteria described by Junker et al. and Baldus et al. 45, 46 The degree of histomorphological regression was classified into four categories: grade 1, o50% vital residual tumor cells (VRCT); grade 2, 10-50% VRCT; grade 3, near complete regression with o10% VRCT; grade 4, complete regression (pathological complete remission). This analysis was performed by two staff pathologists who were blinded for all other clinical data (SEB and UD).
Regression grades 3 and 4 were considered as MaHR compared with grades 1 and 2 constituting MiHR.
Genotyping DNA was extracted from paraffin-embedded tissues from resection boundaries containing exclusively normal cells using a DNA extraction kit (QIAamp, Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Genotyping was performed in 96-well plates by 5 0 nuclease assay (TaqMan) using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Darmstadt, Germany). The pre-developed TaqMan assay ID C_9901536_10 (Applied Biosystems) was used for genotyping of GNAS1 
Statistical analysis
Kaplan-Meier plots and the log-rank test for trend were used to evaluate the relationship between T393C genotypes and clinical outcome. The median follow-up time was 6.2 years (min 2.7 years, max 9.1 years).
To compare data between genotypes, Mann-Whitney U-test was used for continuous variables.
As the T393C polymorphism is described to show a gene dose effect, besides w 2 -test also w 2 trend test was used for categorical variables to check for differences between genotypes.
Binary logistic regression analysis was performed to analyze independent influence of pretherapeutic parameters to histopathological regression. Control of deviation from the Hardy-Weinberg equilibrium was conducted with the public domain program EH and Hardy-Weinberg equilibrium by J Ott. Differences were regarded as statistically significant at a P-value o0.05. Statistical analysis was carried out using SPSS 14.0 (SPSS, Chicago, USA).
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